London Health Sciences Centre
London, Ontario, N6A 5W9, Canada
NCT Number: NCT03905408
The investigators will define the most appropriate safe dose of D50 to heal air leaks in patients that have undergone lung resection surgery
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
London, Ontario, N6A 5W9, Canada
The investigators will define the most appropriate safe dose of D50 to heal air leaks in patients that have undergone lung resection surgery (Phase I study). Air leaks from unhealed lung tissue are one of the most common complications after lung surgery including wedge resection, segmentectomy and lobectomy. Air leaks can lead to a delay in chest tube removal, prolonged pain, increased infections, prolonged hospital stay, and increased costs to the health care system. Different agents have been used to heal air leaks by creating a pleurodesis (adhesions to obliterate the pleural space between the visceral and parietal pleura). The success with these agents has been variable and come with the cost of complications that have restricted their use the post-operative period. There has been recent interest in the use of 50% hypertonic glucose (D50) to create pleurodesis with encouraging reports coming mostly from Asia. The investigators have performed a pilot study using 180 mL of D50 instilled through the chest tube for the management of post lobectomy air leak with very encouraging results. This preliminary study used strict inclusion criteria of only lobectomy patients and excluded all patients with known diabetes or any postoperative hyperglycemia. It is unknown if these patients would have benefitted from D50. Also, the optimal dose of D50 was chosen empirically and never clearly defined by previous work. It has been reported that high doses of D50 have been associated with acute lung injury. It is therefore critical that the optimal safe dose is clarified.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1st dose
Other names: Dextrose
2nd dose
Other names: Dextrose
3rd dose
Other names: Dextrose
4th dose
Other names: Dextrose
Time frame: 1 year
occurrence of treatment related adverse events (Grade 3 and more as assessed to the CTCAE v4.0) at any given dose of D50
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Other
PLeurodesis Using Hypertonic Glucose Administration to Treat Post-operative Air Leaks Following Lung Resection Surgery (PLUG-I): Phase 1
Acronym: PLUG-I
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05628415
Emphysema, Lung Resection
Basel, Switzerland
View Trial DetailsNCT04065880
Postoperative Air Leak, Prolonged Air Leak
Basel, Switzerland
View Trial DetailsNCT07479277
Bronchial Neoplasms, Carcinoma, Bronchogenic
Candiolo, Torino, Italy
View Trial Details